Curaleaf Laboratories

Our team is having an amazing time at The Pharmacy Show! We're here for the second day, so feel free to stop by and say hello at stand B69!

A study recently published in Nature Medicine has reported findings on a cannabis-derived extract, VER-01, in people living with chronic low back pain. The trial involved more than 800 participants and was led by researchers in Hanover, Germany. According to the publication, participants experienced a reduction in reported pain levels over 12 weeks, with further improvements observed during an extension period. Importantly, the study noted no signs of dose escalation, dependence or withdrawal. While more research will be needed, this study adds to a growing body of scientific evidence exploring the role of cannabinoids in managing some of the most prevalent global health challenges. To read more, go to https://brnw.ch/21wWg1K

We’re excited to confirm that Curaleaf Laboratories will be exhibiting at Best Practice Birmingham. 📍 You’ll find us at Stand 45. This is a great opportunity to meet our team, learn more about how we’re supporting healthcare providers, and explore how our solutions can help improve outcomes for patients across primary care. Want to arrange a dedicated meeting during the show? Please get in touch with us to book a time. We look forward to connecting with healthcare leaders who are shaping the future of patient care.

We’re excited to announce that Curaleaf Laboratories will be exhibiting at this year’s The Pharmacy Show — the UK’s leading event for pharmacy professionals and healthcare innovators. 📍 You can find us at Stand B69. This is a fantastic opportunity to connect with our team, learn more about how we’re supporting the pharmacy sector, and explore how our solutions can help you deliver the very best care to your patients. If you’d like dedicated time with us during the show, we’d be delighted to arrange a meeting. Please get in touch to book a slot in advance. We look forward to meaningful conversations, sharing insights, and being part of the future of pharmacy together. See you at The Pharmacy Show!

We’re happy to share to share that Curaleaf Laboratories will be attending the Private Acute Healthcare & Cover Conference. Our team will be there to discuss how we’re supporting innovation, improving access, and working collaboratively across the healthcare ecosystem. If you’d like to set aside time with us during the event, please reach out to book a meeting in advance. We’d love to connect and explore opportunities together. We look forward to engaging conversations and building stronger partnerships across the sector.

The Advisory Council on the Misuse of Drugs has opened a Call for Evidence to review the impact of the 2018 changes to the Misuse of Drugs Regulations, which first introduced medical cannabis in the UK. The review will look at whether the legislation has achieved what it set out to do, highlight any unintended consequences, and make recommendations for how things can be improved. This call is open to: 👩⚕️ Healthcare professionals 🔬 Researchers and academics 🏭 Importers and manufacturers 💚 Patients, families, and people with lived experience ⚖️ Regulators and enforcement bodies At Curaleaf Laboratories, we’re really pleased to see this taking place. It’s a constructive step forward for patients, prescribers, and the wider industry. We’d encourage healthcare professionals and others working in this space to get involved and share their experiences. Your input will help shape the future of medical cannabis in the UK. To respond online, please go to https://brnw.ch/21wW0wK

We’re proud to announce a new partnership between Curaleaf Laboratories and The Medical Cannabis Clinicians Society - a collaboration designed to close the education gap that continues to hold back patient access in the UK. While the UK is now the second largest medical cannabis market in Europe, fewer than 10% of the patients who could benefit are currently receiving treatment. One of the biggest barriers? A lack of education for clinicians. Education has always been central to Curaleaf’s strategy, and this partnership builds on that foundation, creating a stronger platform to empower prescribers and ultimately improve patient care. As Professor Michael Barnes Chair of MCCS, said: “The Society is very grateful to have the support of Curaleaf Laboratories… with the ultimate goal of enabling more patients to benefit from these therapies.” We’re excited to be taking this step forward — because with the right knowledge and support, we believe the UK medical cannabis journey is only just beginning. Read more about our partnership via Business of Cannabis here: https://brnw.ch/21wVVbm

We’re encouraged to see medical cannabis being more widely considered within NHS research, including this new trial investigating whether CBD can help reduce psychotic symptoms in Parkinson’s patients. With three in five people living with Parkinson’s experiencing hallucinations or delusions, the need for new treatment options is clear. At Curaleaf Laboratories, we welcome studies like this that build the clinical evidence base and move us closer to fair, consistent access to medical cannabis. Every step forward in research brings hope for patients, their families, and the healthcare community. Read the full article: https://brnw.ch/21wVSW1

We're heading over to the other side of the river Tyne to attend Pulse 365 Live Newcastle! Find us on stand number 26. Don't miss out on an insightful presentation by our very own Matthew Rawding discussing all things medical cannabis! See you there!

The excitement over the launch of Que Medical Inhalation Device (QMID) continues to grow! We were delighted to see it feature in the recent Chemist+Druggist article. We hope the introduction of this device will bring more confidence to healthcare professionals in prescribing medical cannabis, improving patient access. To read the full article, please go to: https://brnw.ch/21wVGcH (please login/register to view the full article)